MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical trial of DA-1241, ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

A new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Dr. Tahmeena Ali is a family physician ... is a glucagon-like-inhibitor. It is a glucagon-like peptide-1 receptor agonist. This version has been updated. (April 2, 2025): Previous versions ...

The National Family Health Survey (2019-21 ... semaglutide’s role as the first and only approved oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) to achieve a significant reduction ...

I’m Kelly Grant, a health reporter with The Globe and Mail. Yesterday, the Canadian Medical Association Journal published the ...